Imaging mammario molecolare e tomosintesi mammaria digitale nello screening di pazienti con tessuto mammario denso
La densità conta [Imaging molecolare del seno (MBI) e tomosintesi per eliminare il serbatoio]
This study compares molecular breast imaging (MBI) and digital breast tomosynthesis (DBT) in screening patients with dense breast tissue. Breast imaging may help doctors find breast cancer sooner, when it may be easier to treat. Molecular breast imaging (MBI) uses an injection of a small amount of radioactive material that is taken up in tissues of the body that are actively changing, such as breast cancer. A specialized camera, called a gamma camera, takes pictures of the gamma rays emitted by this material. MBI may detect cancers that are not visible on mammograms. This study may help researchers determine how MBI testing compares to DBT screening.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This study includes women age 40-75 who are presenting for breast cancer screening and had mammographically dense breasts on their last mammogram. Participants undergo annual DBT and MBI screening for two years. The primary aim for this study is to compare the rate of detection of invasive cancers between DBT alone vs. the combination of DBT with supplemental MBI at the first year of screening.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48202
- Henry Ford Hospital
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Mayo Clinic in Rochester
-
-
Ohio
-
Toledo, Ohio, Stati Uniti, 43623
- Toledo Clinic Cancer Centers-Toledo
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- M D Anderson Cancer Center
-
-
Wisconsin
-
La Crosse, Wisconsin, Stati Uniti, 54601
- Mayo Clinic Health System-Franciscan Healthcare
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patient is a consenting female age 40-75 years
- Patient is scheduled for routine screening DBT
- Patient is asymptomatic for breast disease
- Patient had heterogeneously dense or extremely dense breasts on most recent prior mammography examination (Breast Imaging Reporting and Data System [BI-RADS] c or d) within 24 months of enrollment
- Patient is able to participate fully in all aspects of the study (completing study visits and study data collection)
- Patient understands and signs the study informed consent
- Patient anticipates being able to return one year after study enrollment to complete the second round of screening
Exclusion Criteria:
- Patient is currently pregnant or plans to become pregnant during the course of the study
- Patient is currently lactating
- Patient has had a prior MBI
- Patient has had a prior whole breast ultrasound (WBUS) for screening, with either a hand-held ultrasound probe or automated system, within 12 months prior to study enrollment
- Patient has had a prior breast MRI
- Patient has had a prior contrast-enhanced mammogram (contrast enhanced spectral mammography [CESM] or contrast-enhanced digital mammography [CEDM])
- Patient is concurrently participating in any other breast imaging research studies that involve undergoing additional breast imaging tests beyond routine screening with mammography, including but not limited to contrast-enhanced mammography, WBUS, MBI, or contrast-enhanced breast MRI
- Patient has had a breast biopsy within 3 months prior to study enrollment
- Patient has had breast surgery within 12 months prior to study enrollment
- Patient is currently undergoing treatment for breast cancer or planning surgery for a high-risk breast lesion (atypical ductal hyperplasia [ADH], atypical lobular hyperplasia [ALH], lobular carcinoma in situ [LCIS], papilloma, radial scar)
- Patient is currently taking a chemoprevention agent for breast cancer risk reduction or osteoporosis prevention (tamoxifen, raloxifene, anastrazole, letrozole, exemestane)
- Patient has a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder study adherence
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: DBT alone
All participants undergo DBT screening |
DBT is standard of care breast screening
Altri nomi:
|
|
Sperimentale: DBT + MBI
All participants undergo DBT screening + supplemental MBI |
DBT is standard of care breast screening
Altri nomi:
Undergo MBI
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Rate of Detection of Invasive Cancers
Lasso di tempo: At year 1 screening
|
Compare the rate of detection of invasive cancers between DBT alone versus (vs.) the combination of digital breast tomosynthesis (DBT) with supplemental molecular breast imaging (MBI) at initial (year 1) screening. For each modality, the detection rate of invasive cancers will be estimated as the proportion of participants in the analysis set who had an invasive cancer detected by the modality and verified by pathology. |
At year 1 screening
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Carrie B. Hruska, M.D., Mayo Clinic in Rochester
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 16-008522
- NCI-2021-12015 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- R01CA239200 (Sovvenzione/contratto NIH degli Stati Uniti)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .